Cargando…

Drug–Drug Interactions of Infectious Disease Treatments in Low‐Income Countries: A Neglected Topic?

Despite recent advances in recognizing and reducing the risk of drug–drug interactions (DDIs) in developed countries, there are still significant challenges in managing DDIs in low‐income countries (LICs) worldwide. In the treatment of major infectious diseases in these regions, multiple factors con...

Descripción completa

Detalles Bibliográficos
Autores principales: McFeely, Savannah J., Yu, Jingjing, Zhao, Ping, Hershenson, Susan, Kern, Steven, Ragueneau‐Majlessi, Isabelle, Hartman, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563420/
https://www.ncbi.nlm.nih.gov/pubmed/30771252
http://dx.doi.org/10.1002/cpt.1397
_version_ 1783426541934346240
author McFeely, Savannah J.
Yu, Jingjing
Zhao, Ping
Hershenson, Susan
Kern, Steven
Ragueneau‐Majlessi, Isabelle
Hartman, Dan
author_facet McFeely, Savannah J.
Yu, Jingjing
Zhao, Ping
Hershenson, Susan
Kern, Steven
Ragueneau‐Majlessi, Isabelle
Hartman, Dan
author_sort McFeely, Savannah J.
collection PubMed
description Despite recent advances in recognizing and reducing the risk of drug–drug interactions (DDIs) in developed countries, there are still significant challenges in managing DDIs in low‐income countries (LICs) worldwide. In the treatment of major infectious diseases in these regions, multiple factors contribute to ineffective management of DDIs that lead to loss of efficacy or increased risk of adverse events to patients. Some of these difficulties, however, can be overcome. This review aims to evaluate the inherent complexities of DDI management in LICs from pharmacological standpoints and illustrate the unique barriers to effective management of DDIs, such as the challenges of co‐infection and treatment settings. A better understanding of comprehensive drug‐related properties, population‐specific attributes, such as physiological changes associated with infectious diseases, and the use of modeling and simulation techniques are discussed, as they can facilitate the implementation of optimal treatments for infectious diseases at the individual patient level.
format Online
Article
Text
id pubmed-6563420
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65634202019-06-17 Drug–Drug Interactions of Infectious Disease Treatments in Low‐Income Countries: A Neglected Topic? McFeely, Savannah J. Yu, Jingjing Zhao, Ping Hershenson, Susan Kern, Steven Ragueneau‐Majlessi, Isabelle Hartman, Dan Clin Pharmacol Ther Reviews Despite recent advances in recognizing and reducing the risk of drug–drug interactions (DDIs) in developed countries, there are still significant challenges in managing DDIs in low‐income countries (LICs) worldwide. In the treatment of major infectious diseases in these regions, multiple factors contribute to ineffective management of DDIs that lead to loss of efficacy or increased risk of adverse events to patients. Some of these difficulties, however, can be overcome. This review aims to evaluate the inherent complexities of DDI management in LICs from pharmacological standpoints and illustrate the unique barriers to effective management of DDIs, such as the challenges of co‐infection and treatment settings. A better understanding of comprehensive drug‐related properties, population‐specific attributes, such as physiological changes associated with infectious diseases, and the use of modeling and simulation techniques are discussed, as they can facilitate the implementation of optimal treatments for infectious diseases at the individual patient level. John Wiley and Sons Inc. 2019-03-21 2019-06 /pmc/articles/PMC6563420/ /pubmed/30771252 http://dx.doi.org/10.1002/cpt.1397 Text en © 2019 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
McFeely, Savannah J.
Yu, Jingjing
Zhao, Ping
Hershenson, Susan
Kern, Steven
Ragueneau‐Majlessi, Isabelle
Hartman, Dan
Drug–Drug Interactions of Infectious Disease Treatments in Low‐Income Countries: A Neglected Topic?
title Drug–Drug Interactions of Infectious Disease Treatments in Low‐Income Countries: A Neglected Topic?
title_full Drug–Drug Interactions of Infectious Disease Treatments in Low‐Income Countries: A Neglected Topic?
title_fullStr Drug–Drug Interactions of Infectious Disease Treatments in Low‐Income Countries: A Neglected Topic?
title_full_unstemmed Drug–Drug Interactions of Infectious Disease Treatments in Low‐Income Countries: A Neglected Topic?
title_short Drug–Drug Interactions of Infectious Disease Treatments in Low‐Income Countries: A Neglected Topic?
title_sort drug–drug interactions of infectious disease treatments in low‐income countries: a neglected topic?
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563420/
https://www.ncbi.nlm.nih.gov/pubmed/30771252
http://dx.doi.org/10.1002/cpt.1397
work_keys_str_mv AT mcfeelysavannahj drugdruginteractionsofinfectiousdiseasetreatmentsinlowincomecountriesaneglectedtopic
AT yujingjing drugdruginteractionsofinfectiousdiseasetreatmentsinlowincomecountriesaneglectedtopic
AT zhaoping drugdruginteractionsofinfectiousdiseasetreatmentsinlowincomecountriesaneglectedtopic
AT hershensonsusan drugdruginteractionsofinfectiousdiseasetreatmentsinlowincomecountriesaneglectedtopic
AT kernsteven drugdruginteractionsofinfectiousdiseasetreatmentsinlowincomecountriesaneglectedtopic
AT ragueneaumajlessiisabelle drugdruginteractionsofinfectiousdiseasetreatmentsinlowincomecountriesaneglectedtopic
AT hartmandan drugdruginteractionsofinfectiousdiseasetreatmentsinlowincomecountriesaneglectedtopic